An analysis of the biomolecule substudy of the EAST–AFNET 4 trial has revealed that biomolecule concentrations in the blood of patients with atrial fibrillation can be used to identify patients at high and low cardiovascular risk. The findings were published in Cardiovascular Research.
Circulating biomolecules identify patients with atrial fibrillation at high risk of cardiovascular events
